A0001 in Friedreich ataxia: Biochemical characterization and effects in a clinical trial

Use of an Adaptive Study Design in Single Ascending-Dose Pharmacokinetics of A0001 (α-Tocopherylquinone) in Healthy Male Subjects

(2011) Amale Hawi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A Phase 3, Double-blind, Placebo-Controlled Trial of Idebenone in Friedreich Ataxia

(2010) David R. Lynch et al.   ARCHIVES OF NEUROLOGY

Regulation of mitochondrial biogenesis

(2010) François R. Jornayvaz et al.   Essays in Biochemistry

A rapid, noninvasive immunoassay for frataxin: Utility in assessment of Friedreich ataxia

(2010) Eric C. Deutsch et al.   MOLECULAR GENETICS AND METABOLISM

Measuring the rate of progression in Friedreich ataxia: Implications for clinical trial design

(2010) Lisa S. Friedman et al.   MOVEMENT DISORDERS

Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARγ pathway as a therapeutic target in Friedreich’s ataxia

(2009) Giovanni Coppola et al.   HUMAN MOLECULAR GENETICS

Clinical experience with high-dose idebenone in Friedreich ataxia

(2009) Jörg B. Schulz et al.   JOURNAL OF NEUROLOGY

The First Cellular Models Based on Frataxin Missense Mutations That Reproduce Spontaneously the Defects Associated with Friedreich Ataxia

(2009) Nadège Calmels et al.   PLoS One

Isolated deficiencies of OXPHOS complexes I and IV are identified accurately and quickly by simple enzyme activity immunocapture assays

(2008) J.H. Willis et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS

Coenzyme Q10and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10therapy

(2008) J. M. Cooper et al.   EUROPEAN JOURNAL OF NEUROLOGY

Idebenone in Friedreich's ataxia

(2008) Caterina Tonon et al.   EXPERT OPINION ON PHARMACOTHERAPY